Aligos Therapeutics (ALGS) EBIAT (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed EBIAT for 5 consecutive years, with -$19.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 75.8% year-over-year to -$19.9 million, compared with a TTM value of -$24.2 million through Dec 2025, up 81.56%, and an annual FY2025 reading of -$24.2 million, up 81.56% over the prior year.
- EBIAT was -$19.9 million for Q4 2025 at Aligos Therapeutics, up from -$31.5 million in the prior quarter.
- Across five years, EBIAT topped out at $43.1 million in Q1 2025 and bottomed at -$82.1 million in Q4 2024.
- Average EBIAT over 5 years is -$23.4 million, with a median of -$22.4 million recorded in 2022.
- Peak annual rise in EBIAT hit 223.59% in 2025, while the deepest fall reached 413.44% in 2025.
- Year by year, EBIAT stood at -$37.7 million in 2021, then surged by 41.97% to -$21.9 million in 2022, then fell by 27.44% to -$27.9 million in 2023, then plummeted by 194.53% to -$82.1 million in 2024, then skyrocketed by 75.8% to -$19.9 million in 2025.
- Business Quant data shows EBIAT for ALGS at -$19.9 million in Q4 2025, -$31.5 million in Q3 2025, and -$15.9 million in Q2 2025.